Trump Executive Order Tracker | Akin Public Policy and Lobbying

Regulatory Relief to Promote Domestic Production of Critical Medicines (Trump EO Tracker)

May 5, 2025

Reading Time : 1 min
Trump Executive Order Tracker | Akin Public Policy and Lobbying

This order streamlines the regulation of manufacturing pharmaceutical products and inputs to facilitate the restoration of a robust domestic pharmaceutical manufacturing base.

Within 180 days, the order directs the Secretary of Health and Human Services, through the FDA Commissioner, to review existing regulations and guidance that pertain to the development of domestic pharmaceutical manufacturing and take steps to eliminate any duplicative or unnecessary requirements in such regulations and guidance; maximize the timeliness and predictability of agency review; and streamline and accelerate the development of domestic pharmaceutical manufacturing.

Within 90 days of the order, the FDA Commissioner is directed to develop and advance improvements to the risk-based inspection regime that ensures routine reviews of overseas manufacturing facilities involved in the supply of United States medicines, funded by increased fees on foreign manufacturing facilities and the FDA Commissioner must publicly disclose the annual number of inspections that the FDA conducts on such foreign facilities.

Within 180 days, the order instructs the Administrator of the Environmental Protection Agency (EPA) to take action to update regulations and guidance that apply to the inspection and approval of new and expanded manufacturing capacity of pharmaceutical products, active pharmaceutical ingredients, key starting materials, and associated raw materials in the United States to eliminate any duplicative or unnecessary requirements and maximize the timeliness and predictability of agency review.

Within 180 days of the order, the Secretary of the Army, acting through the Assistant Secretary of the Army for Civil Works, shall review the nationwide permits issued under section 404 of the Clean Water Act of 1972 (33 U.S.C. 1344) and section 10 of the Rivers and Harbors Appropriation Act of 1899 (33 U.S.C. 403) to determine whether an activity-specific nationwide permit is needed to facilitate the efficient permitting of pharmaceutical manufacturing facilities.

Additional Documentation

Share This Insight

Related Content

Trump Executive Order Tracker

The significant number of executive orders published by the Trump Administration cut across dozens of industries and areas of law. This searchable tool breaks down the orders and their impacts on specific industries and with in-depth analysis of specific orders.

Previous Entries

Trump Executive Order Tracker

December 19, 2025

Sets a strategy for U.S. leadership in 6G technology, emphasizing its importance for national security, AI, robotics, and resilient communications. It directs the Commerce Department’s National Telecommunications and Information Administration to “immediately begin the process of identifying” the 7.125-7.4 GHz band for “reallocation for full-powered commercial licensed use” and study how to reallocate federal systems in the band “to other frequencies” while ensuring that critical defense and electric grid missions remain unaffected. Authorizes studies to explore reallocating portions of the 2.69–2.9 GHz and 4.4–4.94 GHz bands. These efforts aim to accelerate spectrum availability for next-generation networks without compromising existing federal operations. Tasks the State Department and other agencies to lead diplomatic efforts with the ITU to advance U.S. objectives on global spectrum policy.

...

Read More

Trump Executive Order Tracker

December 18, 2025

This order directs the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act. Schedule III drugs are classified as having a potential for abuse less than those drugs in Schedules I and II, a currently accepted medical use in treatment in the United States, and a potential for moderate or low physical dependence or high psychological dependence in the event of drug abuse.

...

Read More

Trump Executive Order Tracker

December 16, 2025

Suspends entry for foreign nationals of additional countries of concern from those previously restricted under Proclamation 10949, as determined by the Secretary of State, the Secretary of Homeland Security, the Attorney General, and the Director of National Intelligence. Additional countries include full suspension of entry for Burkina Faso, Laos, Mali, Niger, Sierra Leone, South Sudan, Syria, Palestinian Authority Documents, and partial suspension of entry for Angola, Antigua and Barbuda, Benin, Cote d ‘Ivoire, Dominica, Gabon, the Gambia, Malawi, Mauritania, Nigeria, Senegal, Tanzania, Tonga, Turkmenistan, Zambia, and Zimbabwe.

...

Read More

Trump Executive Order Tracker

December 15, 2025

Designates illicit fentanyl and its core precursor chemicals as Weapons of Mass Destruction (WMD) and directs the use of national security, criminal, sanctions, intelligence, and military-support authorities to combat fentanyl trafficking. Expands enforcement tools against cartels and foreign terrorist organizations involved in fentanyl production and distributions.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.